BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry

Show simple item record

dc.contributor.author Friebel, Tara M.
dc.contributor.author Andrulis, Irene L.
dc.contributor.author Balmana, Judith
dc.contributor.author Blanco, Amie M.
dc.contributor.author Couch, Fergus J.
dc.contributor.author Daly, Mary B.
dc.contributor.author Domchek, Susan M.
dc.contributor.author Easton, Douglas F.
dc.contributor.author Foulkes, William D.
dc.contributor.author Ganz, Patricia A.
dc.contributor.author Garber, Judy
dc.contributor.author Glendon, Gord
dc.contributor.author Greene, Mark H.
dc.contributor.author Hulick, Peter J.
dc.contributor.author Isaacs, Claudine
dc.contributor.author Jankowitz, Rachel C.
dc.contributor.author Karlan, Beth Y.
dc.contributor.author Kirk, Judy
dc.contributor.author Kwong, Ava
dc.contributor.author Lee, Annette
dc.contributor.author Lesueur, Fabienne
dc.contributor.author Lu, Karen H.
dc.contributor.author Nathanson, Katherine L.
dc.contributor.author Neuhausen, Susan L.
dc.contributor.author Offit, Kenneth
dc.contributor.author Palmero, Edenir I.
dc.contributor.author Sharma, Priyanka
dc.contributor.author Tischkowitz, Marc
dc.contributor.author Toland, Amanda Ewart
dc.contributor.author Tung, Nadine
dc.contributor.author Jansen van Rensburg, Elizabeth
dc.contributor.author Vega, Ana
dc.contributor.author Weitzel, Jeffrey N.
dc.contributor.author GEMO Study Collaborators
dc.contributor.author Hoskins, Kent F.
dc.contributor.author Maga, Tara
dc.contributor.author Parsons, Michael T.
dc.contributor.author McGuffog, Lesley
dc.contributor.author Antoniou, Antonis C.
dc.contributor.author Chenevix-Trench, Georgia
dc.contributor.author Huo, Dezheng
dc.contributor.author Olopade, Olufunmilayo I.
dc.date.accessioned 2020-04-19T10:34:36Z
dc.date.issued 2019-10
dc.description.abstract BRCA1 and BRCA2 (BRCA1/2) pathogenic sequence variants (PSVs) confer elevated risks of multiple cancers. However, most BRCA1/2 PSVs reports focus on European ancestry individuals. Knowledge of the PSV distribution in African descent individuals is poorly understood. We undertook a systematic review of the published literature and publicly available databases reporting BRCA1/2 PSVs also accessed the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) database to identify African or African descent individuals. Using these data, we inferred which of the BRCA PSVs were likely to be of African continental origin. Of the 43,817 BRCA1/2 PSV carriers in the CIMBA database, 469 (1%) were of African descent. Additional African descent individuals were identified in public databases (n = 291) and the literature (n = 601). We identified 164 unique BRCA1 and 173 unique BRCA2 PSVs in individuals of African ancestry. Of these, 83 BRCA1 and 91 BRCA2 PSVs are of likely or possible African origin. We observed numerous differences in the distribution of PSV type and function in African origin versus non‐African origin PSVs. Research in populations of African ancestry with BRCA1/2 PSVs is needed to provide the information needed for clinical management and decision‐making in African descent individuals worldwide. en_ZA
dc.description.department Genetics en_ZA
dc.description.embargo 2020-10-01
dc.description.librarian hj2020 en_ZA
dc.description.sponsorship GEMO: Ligue Nationale Contre le Cancer; the Association “Le cancer du sein, parlons‐en!” Award, Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program and French National Institute of Cancer (INCa). Cancer Research UK Grants. Grant Numbers: C1287/A11990, C1287/A10118. University of California Los Angeles: Jonsson Comprehensive Cancer Center Foundation; Breast Cancer Research Foundation. Mayo Clinic: NIH, NCI Specialized Program of Research Excellence (SPORE), and a grant from the Breast Cancer Research Foundation. Grant Numbers: CA176785, CA192393, CA116201, CA116167. NCI: Intramural Research Program of the US National Cancer Institute, NIH, and by support services contracts NO2‐CP‐11019‐50, N02‐CP‐21013‐63 and N02‐CP‐65504 with Westat, Inc, Rockville, MD. Grant Numbers: N02‐CP‐21013‐63, N02‐CP‐65504, NO2‐CP‐11019‐50. National Cancer Institute. Grant Numbers: RC4CA153828, 5U54CA156732‐07, R25CA112486. FPGMX: Mutua Madrileña Foundation (FMMA). Grant Number: FISPI05/2275. Memorial Sloane Kettering Cancer Center: Breast Cancer Research Foundation, Robert and Kate Niehaus Clinical Cancer Genetics Initiative, Andrew Sabin Research Fund and a Cancer Center Support Grant/Core Grant (P30 CA008748). Grant Number: P30 CA008748. Fox Chase Cancer Center: University of Kansas Cancer Center and Kansas Bioscience Authority Eminent Scholar Program and by Chancellors Distinguished Chair in Biomedical Sciences Professorship. Grant Numbers: R01 CA214545, P30 CA168524, R0 1CA140323. BCFR ‐ all: CA164920 from National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. University of Pennsylvania: National Institutes of Health (NIH) (R01‐CA102776 and R01‐CA083855; Breast Cancer Research Foundation; Susan G. Komen Foundation for the cure, Basser Research Center for BRCA. UPITT/MWH: Hackers for Hope Pittsburgh. VFCTG: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation. Grant Numbers: R01‐CA102776, R01‐CA083855. HRBCP: Hong Kong Sanatorium and Hospital, Dr Ellen Li Charitable Foundation, Kerry Group Kuok Foundation, National Institute of Health1R 03CA130065, and North California Cancer Center. Grant Number: 03CA130065. BMBSA is supported by Cancer Association of South Africa. University California San Francisco: UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center. CIMBA: CIMBA data management and data analysis were supported by Cancer Research – UK grants C12292/A20861, C12292/A11174. ACA is a Cancer Research ‐UK Senior Cancer Research Fellow. GCT and ABS are NHMRC Research Fellows. iCOGS: European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH‐F2‐2009‐223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), National Beth Israel Deaconess Medical Center is supported by Breast Cancer Research Foundation. UKFOCR: Cancer Research UK. GEORGETOWN: Non‐Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI grant P30‐CA051008), Fisher Center for Hereditary Cancer and Clinical Genomics Research, and Swing Fore the Cure. Grant Number: P30‐CA051008. en_ZA
dc.description.uri http://wileyonlinelibrary.com/journal/humu en_ZA
dc.identifier.citation Friebel TM, Andrulis IL, Balmaña J, et al. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Human Mutation. 2019;40:1781–1796. https://doi.org/10.1002/humu.23804. en_ZA
dc.identifier.issn 1059-7794 (print)
dc.identifier.issn 1098-1004 (online)
dc.identifier.other 10.1002/humu.23804
dc.identifier.uri http://hdl.handle.net/2263/74214
dc.language.iso en en_ZA
dc.publisher Wiley en_ZA
dc.rights © 2019 Wiley Periodicals, Inc. This is the pre-peer reviewed version of the following article : BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Human Mutation. 2019;40:1781–1796. https://doi.org/10.1002/humu.23804. The definite version is available at : http://wileyonlinelibrary.com/journal/humu. en_ZA
dc.subject Pathogenic sequence variant (PSV) en_ZA
dc.subject African ancestry en_ZA
dc.subject BRCA1 mutation en_ZA
dc.subject BRCA2 mutation en_ZA
dc.title BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record